Format

Send to

Choose Destination
Pain Manag. 2016 Oct;6(5):427-34. doi: 10.2217/pmt-2015-0009. Epub 2016 Mar 29.

Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.

Author information

1
University of Arizona Cancer Center, Tucson, AZ 85719, USA.
2
INSYS Therapeutics, Chandler, AZ 85286, USA.
3
Carolinas Pain Institute, & The Center for Clinical Research, Winston-Salem, NC 27103, USA.

Abstract

AIM:

To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP).

METHODS:

Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 µg).

RESULTS:

Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse event included nausea (9%) and peripheral edema (9%).

CONCLUSION:

FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850.

KEYWORDS:

breakthrough cancer pain; fentanyl sublingual spray; transmucosal immediate-release fentanyl

PMID:
27020837
DOI:
10.2217/pmt-2015-0009
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center